Robotic-assisted vs. open radical prostatectomy: A machine learning framework for intelligent analysis of patient-reported outcomes from online cancer support groups.

Robotic-assisted vs. open radical prostatectomy: A machine learning framework for intelligent analysis of patient-reported outcomes from online cancer support groups. Urol Oncol. 2018 Sep 17;: Authors: Ranasinghe W, de Silva D, Bandaragoda T, Adikari A, Alahakoon D, Persad R, Lawrentschuk N, Bolton D Abstract BACKGROUND: The advantages of Robot-assisted laparoscopic prostatectomy (RARP) over open radical prostatectomy (ORP) in Prostate cancer perioperatively are well-established, but quality of life is more contentious. Increasingly, patients are utilising online cancer support groups (OCSG) to express themselves. Currently there is no method of analysis of these sophisticated data sources. We have used the PRIME-2 (Patient Reported Information Multidimensional Exploration version 2) framework for automated identification and intelligent analysis of decision-making, functional and emotional outcomes in men undergoing ORP vs. RARP from OCSG discussions. METHODS: The PRIME-2 framework was developed to retrospectively analyse individualised patient-reported information from 5,157 patients undergoing RARP and 579 ORP. The decision factors, side effects, and emotions in 2 groups were analysed and compared using Chi-squared, t tests, and Pearson correlation. RESULTS: There were no differences in Gleason score, Prostate Specific Antigen (PSA), and age between the groups. Surgeon experience and preservation of erectile function (P
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research

Related Links:

ConclusionDT revealed the best correlation to validated structured questionnaires of diverse dimensions with clear potential for quick screening of patients with psychological suffering and in need of further evaluation and support.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
Sometimes after finishing prostate cancer treatment, men get an unwelcome surprise: their prostate-specific antigen (PSA) levels creep higher, suggesting tumors too small to be seen lurk somewhere in the body. This leads to several options. Doctors can continue to monitor a man’s condition with imaging scans. Or, given the anxiety associated with rising PSA, they might try to lower the levels with chemically “castrating” drugs that inhibit testosterone, a hormone that makes prostate tumors grow faster. Following that treatment, called androgen deprivation therapy (ADT), PSA generally declines and may beco...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Living With Prostate Cancer Treatments HPK Source Type: blogs
AbstractPurposeThis  study aimed to investigate the prevalence of sleeping problems in prostate cancer survivors and to explore the role of predisposing, precipitating and perpetuating factors in this process.MethodsUsing a cross-sectional design, 3348 prostate cancer survivors between 2 and 18  years post diagnosis reported experiences of insomnia using the QLQC30, along with their sociodemographic characteristics, health status and treatment(s) received. The EQ5D-5L and QLQPR25 assessed survivors’ overall and prostate cancer–specific health-related quality of life. A hierarchical mu ltiple regressio...
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Conclusions: Results highlight the feasibility and benefits of utilizing PROMIS® CATs to repeatedly assess psychosocial functioning using a web-based method and indicate that web-based interventions may be effective for decreasing psychosocial distress and adverse symptoms among men with APC undergoing hormone therapy. (PsycINFO Database Record (c) 2019 APA, all rights reserved)
Source: Health Psychology - Category: Psychiatry & Psychology Source Type: research
In this study, β2∗ nAChR-containing receptors and lynx1 were identified using pull down studies from the mouse brain (Nissen et al., 2018), while ws-lynx1, SLURP-1 and SLURP-2 has been successfully mixed with human brain tissue to pull down multiple nAChR subtypes (Lyukmanova et al., 2016a,b; Thomsen et al., 2016). To support the in vivo interaction studies, a lynx1KO phenotype was ameliorated by crossing these mice into mutant mice null for α7 and β2 nAChR genes (Miwa et al., 2006). These in vivo studies provide an important biological context for the interactions observed within in vitro systems. ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusion: Genetic associations of diseases considerably vary across populations which necessitates health-related genotyping efforts especially for so far understudied populations. SOM portrayal represents novel promising methods in population genetic research with special strength in visualization-based comparison of SNP data. Introduction Non-communicable polygenic diseases such as cancers, neurodegeneration, cardiovascular, and metabolic disorders have become the most prevalent type worldwide and account for the majority of death events in developed and transition economy countries (Habib and Saha, 2010; Benzi...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Publication date: Available online 18 April 2019Source: Journal of Sport and Health ScienceAuthor(s): Xin Luan, Xiangyang Tian, Haixin Zhang, Rui Huang, Na Li, Peijie Chen, Ru WangAbstractA growing understanding of the benefits of exercise over the past few decades has prompted researchers to take an interest in the possibilities of exercise therapy. Because each sport has its own set of characteristics and physiological complications that tend to appear during exercise training, the effects and underlying mechanisms of exercise remain unclear. Thus, the first step in probing exercise effects on different diseases is the s...
Source: Journal of Sport and Health Science - Category: Sports Medicine Source Type: research
Zhi-Chao Hu1,2,3†, Zu-Cheng Luo1,2,3†, Bing-Jie Jiang1,2,3†, Xin Fu1,2,3, Jiang-Wei Xuan1,2,3, Xiao-Bin Li1,2,3, Yu-Jie Bian1,2,3, Wen-Fei Ni1,2,3* and Ji-Xin Xue1,2,3* 1Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China 2The Second School of Medicine, Wenzhou Medical University, Wenzhou, China 3Bone Research Institute, The Key Orthopaedic Laboratory of Zhejiang Province, Wenzhou, China Osteoarthritis (OA), defined as a long-term progressive joint disease, is characterized by cartilage impairment and ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
ConclusionsChemotherapy-na ïve patients with metastatic castration-resistant prostate cancer experience a substantial burden from their condition. Furthermore, as castration-resistant prostate cancer progresses from the non-metastatic stage to the early metastatic (pre-chemotherapy) stage, certain symptoms become more common and disturb patients’ lives to a greater extent. The resulting conceptual model for metastatic castration-resistant prostate cancer highlights areas that are not adequately assessed with current patient-reported outcome instruments.
Source: The Patient - Patient-Centered Outcomes Research - Category: International Medicine & Public Health Source Type: research
Conclusion: Survivors of CML have a generally favorable outcome. However late relapses may occur (14% in our series) often requiring a change in treatment. This underscores the need to continued monitoring beyond 5 years. Co-morbidities and second malignancies may also occur in many patients, underscoring the need for a holistic follow-up of these patients.DisclosuresBose: Celgene Corporation: Honoraria, Research Funding; Incyte Corporation: Honoraria, Research Funding; Blueprint Medicines Corporation: Research Funding; Constellation Pharmaceuticals: Research Funding; Astellas Pharmaceuticals: Research Funding; Pfizer, Inc...
Source: Blood - Category: Hematology Authors: Tags: 632. Chronic Myeloid Leukemia: Therapy Source Type: research
More News: Anxiety | Cancer | Cancer & Oncology | Laparoscopy | Learning | Legislation | Pain | Prostate Cancer | Prostatectomy | Universities & Medical Training | Urology & Nephrology